As I understand it, the latest guidance from the company was...

As I understand it, the latest guidance from the company was that the OSA results and Nasdaq listing are expected by the end of the quarter (End of March not Feb)

'The trial data is being analysed by Novotech, the contract research organization (‘CRO’) engaged by
Incannex to manage the study and resulting data. Delivery of the final clinical study report is expected in
Q1 2022 and is anticipated to coincide with IHL’s listing on the Nasdaq exchange in the United States. '

(31/01/22 - December 2022 Quarterly Activities Report and Appendix 4C).

Probably no need to be concerned then, if listing and results are not released in Feb.